Hi guys. I recently contacted Cambridge University when I came across this study where they are using a combination of two existing drugs to understand the effects this might have on remylenation, as they have seen good results in animal studies... https://clinicaltrials.gov/ct2/show/NCT05131828 Sadly I am not able to commit to the travel as I'm not doing so well at the moment, but if you are within a 2 hour drive of Cambridge and meet the criteria (see link above) it might be worth contacting them. They will consider people from outside this catchment area, but you need to visit 6 or 7 times over the course of 6 months (not evenly spread out) and funding is limited so they can't cover all your costs if you're too far away. The dates they need to see you are fixed too, so you have to be able to commit to set dates and not miss a visit. I've copied the info below from the university website for more info about what remylenation is... A trial of a possible remyelinating treatment in multiple sclerosis Nerves in the brain and spinal cord are normally surrounded by a protective layer of a substance called myelin (similar to the plastic insulation of an electric cable). In multiple sclerosis (MS), the immune system attacks the myelin, leaving nerve fibres (similar to the metal wire in the cable) unprotected. This causes nerves to malfunction, resulting in multiple sclerosis symptoms. Over time, unprotected nerve fibres die, leading to the progressive phase of MS. To avoid this happening, we are trying to promote remyelination – the process by which myelin is regenerated. Metformin and clemastine, two drugs that are already licenced for diabetes and hay fever respectively, have recently been found to work together to promote remyelination in animals. We believe that this combination may also promote remyelination in people with multiple sclerosis, which could potentially reverse or alleviate symptoms. The purpose of this research is therefore to assess whether metformin and clemastine really can promote remyelination in people. Participants in the trial take several capsules twice daily for 6 months. There is a 50% chance (much like flipping a coin) that these will contain metformin and clemastine. The other half of participants will receive “dummy drugs” called placebos. Neither the participant, nor the trial doctor, knows which treatment they are taking. Remyelination is assessed by an eye test and an MRI scan at the beginning of this six-month period and again at the end. Thought I would share in case it's of interest to anyone on here. You can contact them via email to [email protected] quoting NCT05131828